Clinical features of the patient with multiple primary tumors: Single center experience
INTRODUCTION[|]Multiple primary tumors are the ones that develop in the same patient at the same or different times. They are usually examined under two groups. If the second tumor is diagnosed 6 months after the first tumor is diagnosed, it is named as metachronous tumor. If it is diagnosed in 6 mo...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KARE Publishing
2017-05-01
|
| Series: | İstanbul Kuzey Klinikleri |
| Subjects: | |
| Online Access: | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=nci&un=NCI-67044 |
| _version_ | 1797922530054373376 |
|---|---|
| author | Ali Gökyer Osman Köstek Muhammet Bekir Hacioğlu Bülent Erdoğan Hilmi Kodaz Esma Türkmen İlhan Hacıbekiroğlu Sernaz Uzunoğlu İrfan Çiçin |
| author_facet | Ali Gökyer Osman Köstek Muhammet Bekir Hacioğlu Bülent Erdoğan Hilmi Kodaz Esma Türkmen İlhan Hacıbekiroğlu Sernaz Uzunoğlu İrfan Çiçin |
| author_sort | Ali Gökyer |
| collection | DOAJ |
| description | INTRODUCTION[|]Multiple primary tumors are the ones that develop in the same patient at the same or different times. They are usually examined under two groups. If the second tumor is diagnosed 6 months after the first tumor is diagnosed, it is named as metachronous tumor. If it is diagnosed in 6 months after the first diagnosis, it is called as synchronous tumor. The malignancy of tumors should be proved histologically. At least 2 cm of solid tissue should be present between two tumors. If they are at localized at the same place, a gap of at least 5 years should be present between them. Metastatic disease should be eliminated.This study aimedto review the clinical, demographic, and pathological features of multiple primary tumors, detect the prevalence, compare the results with literature findings, and evaluate and improve the approach to multiple primary tumors.[¤]METHODS[|]A total of 170 patients diagnosed with multiple primary tumors were included in this study. Patient data were obtained from pathology and medical reports of the patients.[¤]RESULTS[|]Most of the multiple primary tumors were metachronous. The number of male patients was more than that of female patients. The median time between double tumors was 3 monthsforsynchronous tumorsand 26 months for metachronous tumors. Synchronous tumors with the highest prevalence of comorbidity were lung–larynx and lung–colon, whereas metachronous tumors with the highest prevalence of comorbidity were lung–bladder, lung–larynx, breast–endometrium, and breast–colon. The history of smoking and alcohol was found to be higher in male patients andsynchronous tumors.[¤]DISCUSSION AND CONCLUSION[|]The detection of the first tumor in the metastatic stage and an accompanying synchronous secondary tumor was found to be a poor prognostic factor. The treatment of the first tumor, smoking, squamous cell histology, and male gender were among the other factors negatively affecting survival,although they were not statistically significant.[¤] |
| first_indexed | 2024-04-10T14:32:52Z |
| format | Article |
| id | doaj.art-76e64257ab034bb584e9a1c09ff30689 |
| institution | Directory Open Access Journal |
| issn | 2148-4902 |
| language | English |
| last_indexed | 2024-04-10T14:32:52Z |
| publishDate | 2017-05-01 |
| publisher | KARE Publishing |
| record_format | Article |
| series | İstanbul Kuzey Klinikleri |
| spelling | doaj.art-76e64257ab034bb584e9a1c09ff306892023-02-15T16:08:42ZengKARE Publishingİstanbul Kuzey Klinikleri2148-49022017-05-0141435110.14744/nci.2017.67044NCI-67044Clinical features of the patient with multiple primary tumors: Single center experienceAli Gökyer0Osman Köstek1Muhammet Bekir Hacioğlu2Bülent Erdoğan3Hilmi Kodaz4Esma Türkmen5İlhan Hacıbekiroğlu6Sernaz Uzunoğlu7İrfan Çiçin8Department of Internal Medicine, Trakya University Faculty of Medicine, Edirne, TurkeyDivision of Medical Oncology, Department of Internal Medicine, Trakya University, Balkan Oncology Hospital, Edirne, TurkeyDivision of Medical Oncology, Department of Internal Medicine, Trakya University, Balkan Oncology Hospital, Edirne, TurkeyDivision of Medical Oncology, Department of Internal Medicine, Trakya University, Balkan Oncology Hospital, Edirne, TurkeyDivision of Medical Oncology, Department of Internal Medicine, Trakya University, Balkan Oncology Hospital, Edirne, TurkeyDivision of Medical Oncology, Department of Internal Medicine, Trakya University, Balkan Oncology Hospital, Edirne, TurkeyDivision of Medical Oncology, Department of Internal Medicine, Trakya University, Balkan Oncology Hospital, Edirne, TurkeyDivision of Medical Oncology, Department of Internal Medicine, Trakya University, Balkan Oncology Hospital, Edirne, TurkeyDivision of Medical Oncology, Department of Internal Medicine, Trakya University, Balkan Oncology Hospital, Edirne, TurkeyINTRODUCTION[|]Multiple primary tumors are the ones that develop in the same patient at the same or different times. They are usually examined under two groups. If the second tumor is diagnosed 6 months after the first tumor is diagnosed, it is named as metachronous tumor. If it is diagnosed in 6 months after the first diagnosis, it is called as synchronous tumor. The malignancy of tumors should be proved histologically. At least 2 cm of solid tissue should be present between two tumors. If they are at localized at the same place, a gap of at least 5 years should be present between them. Metastatic disease should be eliminated.This study aimedto review the clinical, demographic, and pathological features of multiple primary tumors, detect the prevalence, compare the results with literature findings, and evaluate and improve the approach to multiple primary tumors.[¤]METHODS[|]A total of 170 patients diagnosed with multiple primary tumors were included in this study. Patient data were obtained from pathology and medical reports of the patients.[¤]RESULTS[|]Most of the multiple primary tumors were metachronous. The number of male patients was more than that of female patients. The median time between double tumors was 3 monthsforsynchronous tumorsand 26 months for metachronous tumors. Synchronous tumors with the highest prevalence of comorbidity were lung–larynx and lung–colon, whereas metachronous tumors with the highest prevalence of comorbidity were lung–bladder, lung–larynx, breast–endometrium, and breast–colon. The history of smoking and alcohol was found to be higher in male patients andsynchronous tumors.[¤]DISCUSSION AND CONCLUSION[|]The detection of the first tumor in the metastatic stage and an accompanying synchronous secondary tumor was found to be a poor prognostic factor. The treatment of the first tumor, smoking, squamous cell histology, and male gender were among the other factors negatively affecting survival,although they were not statistically significant.[¤]https://jag.journalagent.com/z4/download_fulltext.asp?pdir=nci&un=NCI-67044metachronousmultiple primary tumorssurvivalsynchronous. |
| spellingShingle | Ali Gökyer Osman Köstek Muhammet Bekir Hacioğlu Bülent Erdoğan Hilmi Kodaz Esma Türkmen İlhan Hacıbekiroğlu Sernaz Uzunoğlu İrfan Çiçin Clinical features of the patient with multiple primary tumors: Single center experience İstanbul Kuzey Klinikleri metachronous multiple primary tumors survival synchronous. |
| title | Clinical features of the patient with multiple primary tumors: Single center experience |
| title_full | Clinical features of the patient with multiple primary tumors: Single center experience |
| title_fullStr | Clinical features of the patient with multiple primary tumors: Single center experience |
| title_full_unstemmed | Clinical features of the patient with multiple primary tumors: Single center experience |
| title_short | Clinical features of the patient with multiple primary tumors: Single center experience |
| title_sort | clinical features of the patient with multiple primary tumors single center experience |
| topic | metachronous multiple primary tumors survival synchronous. |
| url | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=nci&un=NCI-67044 |
| work_keys_str_mv | AT aligokyer clinicalfeaturesofthepatientwithmultipleprimarytumorssinglecenterexperience AT osmankostek clinicalfeaturesofthepatientwithmultipleprimarytumorssinglecenterexperience AT muhammetbekirhacioglu clinicalfeaturesofthepatientwithmultipleprimarytumorssinglecenterexperience AT bulenterdogan clinicalfeaturesofthepatientwithmultipleprimarytumorssinglecenterexperience AT hilmikodaz clinicalfeaturesofthepatientwithmultipleprimarytumorssinglecenterexperience AT esmaturkmen clinicalfeaturesofthepatientwithmultipleprimarytumorssinglecenterexperience AT ilhanhacıbekiroglu clinicalfeaturesofthepatientwithmultipleprimarytumorssinglecenterexperience AT sernazuzunoglu clinicalfeaturesofthepatientwithmultipleprimarytumorssinglecenterexperience AT irfancicin clinicalfeaturesofthepatientwithmultipleprimarytumorssinglecenterexperience |